Fortis Healthcare, Apollo Hospitals, Max, Medanta shares rise: Should investors buy after 30% cancer drug price cap?
Fortis Healthcare flagged a risk in a quarterly results development.
· LiveMint Markets
Hospital stocks rallied after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially cutting prices by 20–70% and saving patients ₹2,500 crore annually. Brokerages said earnings effects may be manageable but warned that hospital margins could face pressure.
The analysis
Fortis Healthcare reported ₹2,500 crore, with movement of 30% and 70% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +2.7% on the day at ₹783.80, and has returned -17.5% over three months. It sits 29% below its 52-week high, which means a good deal of bad news was already in the price. The pharma & healthcare sector has moved -1.4% over the same period, so Fortis Healthcare is running 16.1 points behind its peers.
With Fortis Healthcare, Apollo Hospitals and Medanta all implicated, this reads as a Pharma & Healthcare-level move rather than a company-specific one, which is the more durable kind of signal.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- It touches several names at once (FORTIS, APOLLOHOSP, MEDANTA), which points to a sector-level rather than company-specific driver.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads positive.
In this story
Related coverage
Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price
TCS onboards 10,000 freshers in Q2 FY27; plans to hire on demand
Up 15,400% in 5 years, multibagger stock Cupid hits record high - What's fuelling the rally? Check outlook, stop loss
15,410% rally in 5 years! Multibagger Cupid shares jump 3% to hit fresh 52-week high
ICICI Prudential Life Insurance to focus on growing absolute VNB amid slump in FY24